

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name: Name:

Ward: NHI:

Atezolizumab

INITIATION – non-small cell lung cancer second line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

Patient has locally advanced or metastatic non-small cell lung cancer

and

Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC

and

For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain

and

Patient has an ECOG 0-2

and

Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy

and

Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks

and

Baseline measurement of overall tumour burden is documented clinically and radiologically

CONTINUATION – non-small cell lung cancer second line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

Patient's disease has had a complete response to treatment

or

Patient's disease has had a partial response to treatment

or

Patient has stable disease

and

Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

and

No evidence of disease progression

and

The treatment remains clinically appropriate and patient is benefitting from treatment

and

Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent)

and

Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name: Name:

Ward: NHI:

Atezolizumab - *continued*

INITIATION – unresectable hepatocellular carcinoma

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient is currently on treatment with atezolizumab and met all remaining criteria prior to commencing treatment
- or
- Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma
- and
- Patient has preserved liver function (Child-Pugh A)
- and
- Transarterial chemoembolisation (TACE) is unsuitable
- and
- Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma
- or
- Patient received funded lenvatinib before 1 March 2025
- or
- Patient has experienced treatment-limiting toxicity from treatment with lenvatinib
- and
- No disease progression since initiation of lenvatinib
- and
- Patient has an ECOG performance status of 0-2
- and
- To be given in combination with bevacizumab

CONTINUATION – unresectable hepatocellular carcinoma

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

- No evidence of disease progression

I confirm that the above details are correct:

Signed: Date: